Hydrochlorothiazide HYDROCHLOROTHIAZIDE SCIEGEN PHARMACEUTICALS, INC. FDA Approved Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine- 7-sulfonamide 1,1-dioxide and has the following structural formula: Hydrochlorothiazide, USP is a white, or practically white, crystalline powder which is very slightly soluble in water, freely soluble in sodium hydroxide solution, in n -butylamine, and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform and in dilute mineral acids. Each tablet for oral administration contains 25 mg and 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients:microcrystalline cellulose, NF, lactose anhydrous NF, pregelatinized starch NF, sodium lauryl sulfate NF, silicon dioxide NF and magnesium stearate, NF. hydrochlorothiazide-structure

Drug Facts

Composition & Profile

Strengths
25 mg 50 mg
Quantities
30 bottles 30 tablets 10 bottles 1000 tablets 30 tablet 30 count 1000 tablet 1000 count
Treats Conditions
Indications And Usage Hydrochlorothiazide Tablets Are Indicated As Adjunctive Therapy In Edema Associated With Congestive Heart Failure Hepatic Cirrhosis And Corticosteroid And Estrogen Therapy Hydrochlorothiazide Tablets Have Also Been Found Useful In Edema Due To Various Forms Of Renal Dysfunction Such As Nephrotic Syndrome Acute Glomerulonephritis And Chronic Renal Failure Hydrochlorothiazide Tablets Are Indicated In The Management Of Hypertension Either As The Sole Therapeutic Agent Or To Enhance The Effectiveness Of Other Antihypertensive Drugs In The More Severe Forms Of Hypertension Use In Pregnancy Routine Use Of Diuretics During Normal Pregnancy Is Inappropriate And Exposes Mother And Fetus To Unnecessary Hazard Diuretics Do Not Prevent Development Of Toxemia Of Pregnancy And There Is No Satisfactory Evidence That They Are Useful In The Treatment Of Toxemia Edema During Pregnancy May Arise From Pathologic Causes Or From The Physiologic And Mechanical Consequences Of Pregnancy Thiazides Are Indicated In Pregnancy When Edema Is Due To Pathologic Causes Just As They Are In The Absence Of Pregnancy See Precautions Pregnancy Dependent Edema In Pregnancy Resulting From Restriction Of Venous Return By The Gravid Uterus Is Properly Treated Through Elevation Of The Lower Extremities And Use Of Support Stockings Use Of Diuretics To Lower Intravascular Volume In This Instance Is Illogical And Unnecessary During Normal Pregnancy There Is Hypervolemia Which Is Not Harmful To The Fetus Or The Mother In The Absence Of Cardiovascular Disease However It May Be Associated With Edema Rarely Generalized Edema If Such Edema Causes Discomfort Increased Recumbency Will Often Provide Relief Rarely This Edema May Cause Extreme Discomfort Which Is Not Relieved By Rest In These Instances A Short Course Of Diuretic Therapy May Provide Relief And Be Appropriate
Pill Appearance
Shape: round Color: white Imprint: 112;S;G

Identifiers & Packaging

Container Type BOTTLE
UPC
0350228111300 0350228111102 0350228112109
UNII
0J48LPH2TH
Packaging

HOW SUPPLIED: Hydrochlorothiazide tablets, USP are available containing 25 mg and 50 mg hydrochlorothiazide, USP The 25 mg tablets are White to off white, round shaped bevel edge, scored tablets debossed with 111 on one side of the tablet and S to the left of the score and G to the right of the score on the other side. They are available as follows: NDC 50228-111-30 bottles of 30 tablets NDC 50228-111-10 bottles of 1000 tablets The 50 mg tablets are White to off white, round shaped bevel edge, scored tablets debossed with 112 on one side of the tablet and S to the left of the score and G to the right of the score on the other side. They are available as follows: NDC 50228-112-30 bottles of 30 tablets NDC 50228-112-10 bottles of 1000 tablets Store at 20° to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.; PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 25 mg (30 tablet Bottle) 50228-111-30 25 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 25 mg, 30 count.; PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 25 mg (1000 tablet Bottle) 50228-111-10 25 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 25 mg, 1000 count.; PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (30 tablet Bottle) 50228-112-30 50 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 50 mg, 30 count.; PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (1000 tablet Bottle) 50228-112-10 50 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 50 mg, 1000 count.

Package Descriptions
  • HOW SUPPLIED: Hydrochlorothiazide tablets, USP are available containing 25 mg and 50 mg hydrochlorothiazide, USP The 25 mg tablets are White to off white, round shaped bevel edge, scored tablets debossed with 111 on one side of the tablet and S to the left of the score and G to the right of the score on the other side. They are available as follows: NDC 50228-111-30 bottles of 30 tablets NDC 50228-111-10 bottles of 1000 tablets The 50 mg tablets are White to off white, round shaped bevel edge, scored tablets debossed with 112 on one side of the tablet and S to the left of the score and G to the right of the score on the other side. They are available as follows: NDC 50228-112-30 bottles of 30 tablets NDC 50228-112-10 bottles of 1000 tablets Store at 20° to 25°C (68 to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 25 mg (30 tablet Bottle) 50228-111-30 25 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 25 mg, 30 count.
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 25 mg (1000 tablet Bottle) 50228-111-10 25 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 25 mg, 1000 count.
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (30 tablet Bottle) 50228-112-30 50 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 50 mg, 30 count.
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 50 mg (1000 tablet Bottle) 50228-112-10 50 mg This is a picture of the label Hydrochlorothiazide tablets, USP, 50 mg, 1000 count.

Overview

Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro- 2H -1,2,4-benzothiadiazine- 7-sulfonamide 1,1-dioxide and has the following structural formula: Hydrochlorothiazide, USP is a white, or practically white, crystalline powder which is very slightly soluble in water, freely soluble in sodium hydroxide solution, in n -butylamine, and in dimethylformamide; sparingly soluble in methanol; insoluble in ether, in chloroform and in dilute mineral acids. Each tablet for oral administration contains 25 mg and 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients:microcrystalline cellulose, NF, lactose anhydrous NF, pregelatinized starch NF, sodium lauryl sulfate NF, silicon dioxide NF and magnesium stearate, NF. hydrochlorothiazide-structure

Indications & Usage

: Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.

Dosage & Administration

: Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response. Adults: For Edema: The usual adult dosage is 25 mg to 100 mg daily as a single or divided dose. Many patients with edema respond to intermittent therapy, i.e., administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting undesirable electrolyte imbalance are less likely to occur. For Control of Hypertension: The usual initial dose in adults is 25 mg daily given as a single dose. The dose may be increased to 50 mg daily, given as a single or two divided doses. Doses above 50 mg are often associated with marked reductions in serum potassium (see also PRECAUTIONS ). Patients usually do not require doses in excess of 50 mg of hydrochlorothiazide daily when used concomitantly with other antihypertensive agents. Infants and Children: For Diuresis and For Control of Hypertension: The usual pediatric dosage is 0.5 to 1 mg per pound (1 to 2 mg/kg) per day in single or two divided doses, not to exceed 37.5 mg per day in infants up to 2 years of age or 100 mg per day in children 2 to 12 years of age. In infants less than 6 months of age, doses up to 1.5 mg per pound (3 mg/kg) per day in two divided doses may be required. (See PRECAUTIONS: Pediatric Use ).

Warnings & Precautions
WARNINGS: Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may add to or potentiate the action of other antihypertensive drugs. Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported. Lithium generally should not be given with diuretics (see PRECAUTIONS: Drug Interactions ). Acute Myopia and Secondary Angle-Closure Glaucoma: Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Contraindications

: Anuria. Hypersensitivity to this product or to other sulfonamide-derived drugs.

Adverse Reactions

The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity. Body as a Whole: Weakness. Cardiovascular: Hypotension including orthostatic hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs). Digestive: Pancreatitis, jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis, cramping, constipation, gastric irritation, nausea, anorexia. Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia. Hypersensitivity: Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash, purpura. Metabolic: Electrolyte imbalance (see PRECAUTIONS ), hyperglycemia, glycosuria, hyperuricemia. Musculoskeletal: Muscle spasm. Nervous System/Psychiatric: Vertigo, paresthesias, dizziness, headache, restlessness. Renal: Renal failure, renal dysfunction, interstitial nephritis (see WARNINGS ). Skin: Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia. Special Senses: Transient blurred vision, xanthopsia. Urogenital: Impotence. Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.


Similar Drugs

Related medications based on brand, generic name, substance, active ingredients.

View all similar drugs →